Disclosed is a pharmaceutical which has an excellent therapeutic effect on cerebral infarction and an excellent ameliorating effect on a dysfunction or neurologic deficit induced by cerebral infarction and produces little adverse side effects. A pharmaceutical comprising a combination of N-(3-chloro-4-morpholin-4-yl)phenyl-N'- hydroxyimidoformamide with a thrombolytic agent such as urokinase, alteplase, desmoteplase, tisokinase, nasaruplase, nateplase, pamiteplase, monteplase or batroxobin.
PHARMACEUTICAL FOR USE IN THE TREATMENT OF CEREBRAL INFARCTION